Product Description
Rationale IDL-2965 is an oral, small-molecule antagonist of integrins ?v?1, ?v?3, and ?v?6 in clinical development for interstitial lung diseases and liver fibrosis that exhibits potent antifibrotic effects in animal models.
Mechanisms of Action: aVb6 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Indalo Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Idiopathic Pulmonary Fibrosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Indalo (IDL)-2965-IPF-001 | P1 |
Terminated |
Idiopathic Pulmonary Fibrosis |
2020-03-29 |
52% |